These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22831888)

  • 21. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial.
    Kranke P; Eberhart L; Motsch J; Chassard D; Wallenborn J; Diemunsch P; Liu N; Keh D; Bouaziz H; Bergis M; Fox G; Gan TJ
    Br J Anaesth; 2013 Dec; 111(6):938-45. PubMed ID: 23872464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial.
    de Morais LC; Sousa AM; Flora GF; Grigio TR; Guimarães GMN; Ashmawi HA
    Acta Anaesthesiol Scand; 2018 Apr; 62(4):483-492. PubMed ID: 29315462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Prophylactic Antiemetic Efficacy of Aprepitant Plus Palonosetron Versus Aprepitant Plus Ramosetron in Patients at High Risk for Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Prospective Randomized-controlled Trial.
    Choi EK; Kim DG; Jeon Y
    Surg Laparosc Endosc Percutan Tech; 2016 Oct; 26(5):354-357. PubMed ID: 27636144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine.
    Tarkkila P; Törn K; Tuominen M; Lindgren L
    Acta Anaesthesiol Scand; 1995 Oct; 39(7):983-6. PubMed ID: 8848904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous, oral, and the combination of intravenous and oral ramosetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, controlled trial.
    Ryu JH; Jeon YT; Hwang JW; Oh AY; Moon JY; Ro YJ; Kim CS; Chen C; Apfel CC; Do SH
    Clin Ther; 2011 Sep; 33(9):1162-72. PubMed ID: 21856001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant.
    Diemunsch P; Apfel C; Gan TJ; Candiotti K; Philip BK; Chelly J; Carides AD; Evans JK; Ho TW; Reiss T
    Curr Med Res Opin; 2007 Oct; 23(10):2559-65. PubMed ID: 17845742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo-controlled noninferiority study.
    Dewinter G; Teunkens A; Vermeulen K; Devroe S; Van Hemelrijck J; Meuleman C; Vergote I; Fieuws S; Van de Velde M; Rex S
    Eur J Anaesthesiol; 2016 Feb; 33(2):96-103. PubMed ID: 26086285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery.
    Vallejo MC; Phelps AL; Ibinson JW; Barnes LR; Milord PJ; Romeo RC; Williams BA; Sah N
    Plast Reconstr Surg; 2012 Feb; 129(2):519-526. PubMed ID: 21987042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron.
    Jones S; Strobl R; Crosby D; Burkard JF; Maye J; Pellegrini JE
    AANA J; 2006 Apr; 74(2):127-32. PubMed ID: 16617916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery.
    Sah N; Ramesh V; Kaul B; Dalby P; Shestak K; Vallejo MC
    J Clin Anesth; 2009 Jun; 21(4):249-52. PubMed ID: 19502023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiemesis after total joint arthroplasty: does a single preoperative dose of aprepitant reduce nausea and vomiting?
    DiIorio TM; Sharkey PF; Hewitt AM; Parvizi J
    Clin Orthop Relat Res; 2010 Sep; 468(9):2405-9. PubMed ID: 20419358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind comparison of granisetron, promethazine, or a combination of both for the prevention of postoperative nausea and vomiting in females undergoing outpatient laparoscopies.
    Gan TJ; Candiotti KA; Klein SM; Rodriguez Y; Nielsen KC; White WD; Habib AS
    Can J Anaesth; 2009 Nov; 56(11):829-36. PubMed ID: 19730966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-emetic prophylaxis with oral tropisetron and/or dexamethasone.
    Eberhart LH; Büning EK; Folz B; Maybauer DM; Kästner M; Kalder M; Koch T; Kranke P; Wulf H
    Eur J Clin Invest; 2006 Aug; 36(8):580-7. PubMed ID: 16893381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial.
    Grigio TR; Sousa AM; Magalhães GGN; Ashmawi HA; Vieira JE
    Clinics (Sao Paulo); 2020; 75():e1688. PubMed ID: 32901672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects.
    Salman FT; DiCristina C; Chain A; Afzal AS
    J Pediatr Surg; 2019 Jul; 54(7):1384-1390. PubMed ID: 30381138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
    Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
    Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized double blind study to evaluate efficacy of palonosetron with dexamethasone versus palonosetron alone for prevention of postoperative and postdischarge nausea and vomiting in subjects undergoing laparoscopic surgeries with high emetogenic risk.
    Blitz JD; Haile M; Kline R; Franco L; Didehvar S; Pachter HL; Newman E; Bekker A
    Am J Ther; 2012 Sep; 19(5):324-9. PubMed ID: 21519222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of current antiemetic practices on patient outcomes: a prospective study on high-risk patients.
    White PF; O'Hara JF; Roberson CR; Wender RH; Candiotti KA;
    Anesth Analg; 2008 Aug; 107(2):452-8. PubMed ID: 18633023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ramosetron with combined ramosetron and midazolam for preventing postoperative nausea and vomiting in patients at high risk following laparoscopic gynaecological surgery.
    Park EY; Lee SK; Kang MH; Lim KJ; Kim YS; Choi E; Park YH
    J Int Med Res; 2013 Jun; 41(3):654-63. PubMed ID: 23660085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.